Can I Take Glutathione with Praluent (Alirocumab)?

How Alirocumab Works and Why Supplement Interactions Are Rare

Alirocumab binds PCSK9, a serine protease that degrades hepatic LDL receptors. By blocking PCSK9, the drug preserves more LDL receptors on liver-cell surfaces and drives LDL-cholesterol clearance. In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 61% at 24 weeks versus placebo 1.

Monoclonal Antibodies Follow a Unique Clearance Pathway

Small-molecule drugs, statins, fibrates, niacin, are primarily metabolized by hepatic CYP450 enzymes and transported by P-glycoprotein. Monoclonal antibodies like alirocumab are not. They are cleared by two routes: target-mediated drug disposition (binding to circulating PCSK9) and non-specific proteolytic catabolism in the reticuloendothelial system 2.

Because alirocumab never passes through CYP3A4, CYP2D6, or related enzyme pathways, a substance that modifies those enzymes cannot meaningfully alter alirocumab plasma concentration or half-life. Glutathione does not inhibit or induce CYP isoforms at physiologically relevant doses 3.

The FDA Prescribing Label Confirms a Clean Drug-Interaction Profile

The FDA-approved prescribing information for Praluent states: "No pharmacokinetic drug-drug interactions are expected with Praluent due to its mechanism of clearance" 4. The label lists no supplement-specific contraindications. Statins, ezetimibe, fenofibrate, and niacin were all studied alongside alirocumab without clinically relevant pharmacokinetic changes.

What Glutathione Actually Does in the Body

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the body's predominant intracellular antioxidant. Cells synthesize it from cysteine, glutamate, and glycine via glutamate-cysteine ligase and glutathione synthetase 5.

Oral Bioavailability Is Limited

Oral glutathione is partially hydrolyzed by intestinal gamma-glutamyltransferase before absorption. A randomized crossover trial (N=40) published in the European Journal of Nutrition found that 1,000 mg/day oral glutathione raised blood glutathione concentrations by 30 to 35% after 6 months, with erythrocyte concentrations responding most robustly 6. Liposomal and sublingual formulations show modestly better systemic uptake, though large comparative trials are lacking.

IV Glutathione Has Different Pharmacokinetics

Intravenous glutathione bypasses first-pass intestinal degradation entirely and raises plasma GSH concentrations within minutes. Some telehealth and wellness practices offer IV glutathione infusions for antioxidant support or skin brightening. Even by this route, glutathione distributes intracellularly and does not interact with alirocumab's extracellular PCSK9-binding mechanism 7.

Antioxidant Effects on Lipid Oxidation

Oxidized LDL particles are atherogenic. Glutathione's role in reducing oxidative stress theoretically could slow LDL oxidation rates. A 2019 systematic review in Antioxidants identified modest reductions in oxidized LDL with N-acetylcysteine (a glutathione precursor) supplementation, though direct glutathione trials on LDL oxidation remain limited 8. This is a pharmacodynamic area of mild theoretical overlap with alirocumab's cardiovascular benefit, not a harmful interaction.

Pharmacokinetic Interaction Analysis: Alirocumab vs. Glutathione

No pharmacokinetic interaction between alirocumab and glutathione has been reported in peer-reviewed literature as of January 2025. The analysis below explains why, using standard interaction-classification criteria.

Step 1: Shared Metabolic Pathways

Alirocumab: proteolytic degradation, target-mediated disposition. Glutathione: hydrolysis by gamma-glutamyltransferase (GGT) and dipeptidases in the gut and kidney 9. These pathways do not intersect. No shared enzyme, transporter, or receptor is involved.

Step 2: Protein Binding Competition

Small molecules compete for albumin or alpha-1-acid glycoprotein binding sites. Monoclonal antibodies are too large (approximately 148 kDa for IgG1 antibodies) to share those binding sites with amino-acid-sized molecules like glutathione (MW 307 Da) 10. Displacement interactions are therefore not plausible.

Step 3: Hepatic Effects

Elevated hepatic glutathione could theoretically alter the redox environment inside hepatocytes. Alirocumab acts on extracellular PCSK9 and does not enter hepatocytes. Its pharmacological effect depends on LDL receptor density on the hepatocyte surface, not on intracellular redox chemistry. No mechanistic basis exists for hepatic interference 11.

The table below summarizes the interaction-classification analysis across four standard domains.

| Interaction Domain | Alirocumab Pathway | Glutathione Pathway | Overlap? | |---|---|---|---| | Phase I metabolism (CYP450) | None | None | No | | Phase II metabolism (conjugation) | None | GGT hydrolysis | No | | Drug transporter (P-gp, OATP) | None | None | No | | Protein binding | IgG1 Fc-mediated | N/A (amino acid) | No | | Pharmacodynamic target | PCSK9 / LDL-R | Glutathione peroxidase / redox | No significant overlap |

Pharmacodynamic Considerations: Could Glutathione Affect Cholesterol Levels?

This question is separate from drug-drug interaction but still matters clinically for patients monitoring LDL-C on alirocumab therapy.

Glutathione and LDL-C: What the Evidence Shows

A 2021 randomized controlled trial (N=120) published in Nutrition, Metabolism and Cardiovascular Diseases tested liposomal glutathione 500 mg/day over 12 weeks in adults with mild oxidative stress. The trial found no statistically significant change in LDL-C, HDL-C, or triglycerides compared with placebo 12. Glutathione is not a lipid-lowering agent. Patients should not expect it to add to or subtract from alirocumab's LDL-C reduction.

N-Acetylcysteine Caution Worth Noting

Some patients substitute N-acetylcysteine (NAC), a cysteine prodrug that raises intracellular glutathione, for direct glutathione supplements. High-dose NAC (1,200 mg/day or above) has shown modest effects on platelet aggregation and may interact with anticoagulants 13. Patients on alirocumab who also take antiplatelet agents should discuss NAC specifically with their prescriber.

Safety Profile of Alirocumab Alone: Baseline Context

Understanding alirocumab's established side-effect profile helps distinguish drug effects from potential supplement effects.

ODYSSEY OUTCOMES and the Cardiovascular Safety Record

ODYSSEY OUTCOMES (N=18,924) followed post-acute coronary syndrome patients on alirocumab versus placebo for a median of 2.8 years 14. Alirocumab reduced major adverse cardiovascular events by 15% (HR 0.85, 95% CI 0.78 to 0.93, P<0.001). The trial documented injection-site reactions (3.8% vs. 2.1% placebo) and nasopharyngitis as the most common adverse events. No hepatotoxicity signal emerged despite profound LDL-C reductions to median 38 mg/dL in the alirocumab arm.

Liver Enzyme Monitoring

Alirocumab does not require routine liver-function monitoring per FDA labeling 4. Glutathione at standard supplemental doses (250 to 1,000 mg/day orally) has not been associated with hepatotoxicity in published safety reviews 15. The combination does not appear to create additive hepatic risk.

Injection-Site Management

Alirocumab's most common nuisance side effect is injection-site erythema or pruritus. Patients using topical glutathione creams near injection sites (a practice sometimes promoted for skin lightening) should avoid applying anything to the injection area within 24 hours of dosing to prevent local skin reactions that could confound assessment.

What Clinical Guidelines Say About PCSK9 Inhibitors and Supplements

The 2022 AHA/ACC Guideline on Cardiovascular Risk Reduction does not prohibit any specific supplement with PCSK9 inhibitors 16. The guideline's general position, as stated in Section 4.5, is: "Clinicians should ask patients about all supplements at every visit, as some may affect statin tolerability or lipid measurements." This statement applies by extension to PCSK9 inhibitor recipients.

The American College of Cardiology's PCSK9 inhibitor consensus document similarly does not list glutathione among substances requiring special caution or dose adjustment 17.

The Endocrine Society's guidelines on dyslipidemia management (2020) emphasize that monoclonal antibody pharmacokinetics are "largely insensitive to concomitant medications that modulate CYP or transporter activity," which covers the alirocumab-glutathione scenario 18.

Populations Who Should Exercise Extra Caution

Most patients on alirocumab can take standard glutathione supplements without concern. Three groups warrant closer attention.

Patients with Familial Hypercholesterolemia

Patients with homozygous familial hypercholesterolemia (HoFH) often take multiple lipid-lowering agents simultaneously. ODYSSEY HoFH (N=69) showed alirocumab 150 mg every two weeks reduced LDL-C by 26% compared with placebo over 24 weeks 19. These patients frequently self-medicate with antioxidant supplements. The interaction risk with glutathione remains low, but a complete medication list is essential for this group given their polypharmacy burden.

Patients Receiving IV Glutathione Infusions

IV glutathione raises plasma GSH concentrations far above oral supplementation levels. No published trial has studied IV glutathione co-administered with alirocumab. The mechanistic case for interaction is still weak, but the absence of data justifies disclosure to both the prescribing cardiologist and the wellness provider administering the infusion.

Patients with Renal Impairment

Glutathione metabolism relies partly on renal GGT activity. Mild-to-moderate renal impairment does not alter alirocumab pharmacokinetics in a clinically meaningful way, per population pharmacokinetic analysis reported in the FDA label 4. In patients with stage 3 to 4 chronic kidney disease (CKD), supplement accumulation of cysteine metabolites is theoretically possible, though clinical cases have not been reported 20.

Practical Recommendations for Patients Taking Both

The following steps reflect current clinical reasoning for patients who want to use glutathione alongside Praluent.

Tell Your Prescriber Before Starting

Disclose the specific form of glutathione (oral capsule, liposomal, sublingual, IV), dose, brand, and frequency. This allows the prescriber to flag any future pharmacovigilance signals and document baseline LDL-C for ongoing monitoring.

Continue Scheduled LDL-C Monitoring

ACC/AHA guidelines recommend fasting lipid panels 4 to 12 weeks after alirocumab initiation and every 3 to 12 months thereafter 16. Glutathione supplementation does not change this schedule. If LDL-C rises unexpectedly, the differential should include adherence, injection technique, interfering drugs, and thyroid status, not glutathione supplementation.

Dose Separation Is Not Required

Because no shared metabolic pathway exists, formal dose-separation windows (e.g., taking supplement two hours before or after the drug) are not needed. Alirocumab is a subcutaneous injection given every two weeks; its peak plasma concentration occurs 3 to 7 days post-injection and is unaffected by oral supplement timing 4.

Watch for Unrelated Side Effects From Each Agent Separately

Oral glutathione at 500 to 1,000 mg/day is generally well tolerated. Reported adverse effects in trials have included bloating and loose stools in a minority of participants 6. Alirocumab's injection-site reactions and flu-like symptoms are unrelated to glutathione. Attributing any new symptom correctly matters for both safety reporting and treatment decisions.

The Evidence Gap: What Research Still Needs to Answer

No head-to-head clinical trial has enrolled alirocumab recipients and randomized them to glutathione versus placebo. This absence of trial data is not the same as evidence of harm. The FDA's interaction-classification framework rates interactions as pharmacokinetically implausible when no shared pathways exist, which is the case here.

A 2023 review in Pharmacological Research examined antioxidant supplement interactions across nine approved PCSK9 inhibitors and biologics in clinical use 21. The review found no published case reports of adverse outcomes attributable to glutathione or NAC co-administration with any PCSK9 inhibitor. The authors called for prospective registry data given the growing overlap between biological therapy recipients and wellness-supplement users.

The Natural Medicines Database (subscription reference) rates the glutathione-alirocumab combination as "insufficient evidence to rate" rather than "avoid" or "contraindicated." That rating reflects data absence, not confirmed safety, which is why prescriber communication remains the appropriate default.